The Conversation (0)
Akers Biosciences announced a set of changes to its board of directors.
Akers Biosciences (NASDAQ:AKER) announced a set of changes to its board of directors.
As quoted in the press release:
At the Company’s annual shareholder meeting held yesterday in Philadelphia, PA, shareholders elected three new non-executive directors to the Board, Bill J. White, Richard C. Tarbox III and Christopher C. Schreiber; together with John J. Gormally, the Company’s Chief Executive Officer and Raymond F. Akers Jr., Ph.D., the Company’s Vice Chairman and Chief Scientific Director.
John J. Gormally has served as the Company’s Chief Executive Officer since November 2015. Mr. Gormally has over 30 years of experience in the healthcare industry. He joined Becton, Dickinson and Company, a medical technology company that manufactures and sells a range of medical supplies and diagnostic equipment, in 1978 as a senior sales representative. Mr. Gormally served in a wide range of positions with Becton through 2013, focusing primarily on commercialization of Becton’s products and fostering sales growth. From 1999 to 2001, Mr. Gormally served as the Vice President of U.S. Sales and Operations for ConvaTec, a former division of Bristol-Myers Squibb Company. From 2001 to 2002, he served as the Vice President of Global Sales and Marketing for BEI Medical Systems Company, Inc., prior to rejoining Becton from 2002 to 2013. In 2013, Mr. Gormally founded Gormally Elite Medical LLC, a healthcare consulting firm that specializes in human resources and developing go-to-market commercialization strategies.
Click here to read the full press release.
Source: www.marketwired.com
